<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03800173</url>
  </required_header>
  <id_info>
    <org_study_id>BCX4430-106</org_study_id>
    <secondary_id>DMID18-0013</secondary_id>
    <secondary_id>272201300017C-18-0-1</secondary_id>
    <nct_id>NCT03800173</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430</brief_title>
  <official_title>A Phase 1 Double-blind, Placebo Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Galidesivir (BCX4430) Administered as Single Doses Via Intravenous Infusion in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BioCryst Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>BioCryst Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics
      of galidesivir following administration of single doses by IV infusion
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This single ascending dose study will evaluate the safety, tolerability, and PK of single
      doses of galidesivir vs. placebo administered as IV infusions in healthy subjects enrolled in
      up to four dose cohorts of 8 subjects each. A single dose of study drug will be administered
      per cohort: 6 subjects will receive galidesivir IV, and 2 subjects will receive matching
      placebo.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 10, 2018</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Actual">April 30, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number and percent of subjects with treatment emergent adverse events and serious adverse events</measure>
    <time_frame>absolute number and change from baseline through the end of the study, approximately 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number and percent of subjects with laboratory abnormalities</measure>
    <time_frame>absolute number and change from baseline through the end of the study, approximately 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number and percentage of subjects with electrocardiogram changes in PR, QRS, QT, RR and QTcF intervals</measure>
    <time_frame>absolute and change from baseline through the end of the study, approximately 21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number and percent of subjects with changes to echocardiogram</measure>
    <time_frame>absolute and change from baseline through day 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>number and percent of subjects with changes following 24 hour cardiac telemetry</measure>
    <time_frame>absolute and change from baseline through 24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>plasma PK parameters - Cmax (maximum plasma concentration)</measure>
    <time_frame>plasma PK parameters are based on sampling over a 21 day period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma PK parameters - AUC (Area under the curve)</measure>
    <time_frame>plasma PK parameters are based on sampling over a 21 day period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>renal clearance</measure>
    <time_frame>urine PK parameters are based on sampling over a 5 day period</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Marburg Virus Disease</condition>
  <arm_group>
    <arm_group_label>Galidesivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galidesivir IV infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo IV infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>galidesivir</intervention_name>
    <description>galidesivir IV infusion</description>
    <arm_group_label>Galidesivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo IV infusion</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  written informed consent

          -  males and non-pregnant, non-lactating females

          -  BMI 19.0-32.0

          -  willing to abide by contraceptive requirements

          -  normal vitals

          -  willing to abide by study procedures and restrictions

        Exclusion Criteria:

          -  clinically significant medical condition or medical history or psychiatric condition
             or history of psychiatric condition

          -  abnormal cardiac finding, or laboratory/urinalysis abnormality at screening

          -  known family history of sudden death or long QT syndrome, family or personal history
             of QT prolongation, or arrhythmia that required medical intervention

          -  current participation in any other investigational drug study or participation in an
             investigational drug study within 3 months of screening visit

          -  use of prescription, OTC, or herbal medications during study or use of any specified
             medications within 30 days prior to study

          -  Recent or current history of alcohol or drug abuse

          -  Regular use of tobacco or nicotine products

          -  Positive serology for HBV, HCV, or HIV

          -  history of severe adverse reaction to or known sensitivity to any drug

          -  pregnant, lactating, or planning to become pregnant within 30 days of the study. Male
             subjects with pregnant female partners are excluded
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel Dickerson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA Health Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 12, 2018</study_first_submitted>
  <study_first_submitted_qc>January 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Marburg Virus Disease</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

